Learning Objectives:

1.       Review The Hydrodynamics of Glomerular Filtration

2.       Combine The Additive Impact Of ACE-I and SGLT-2

3.       Inhibition in the Treatment Cardiorenal Disease

 Faculty Disclosure:

David Cherney, MD CM, PhD, FRCP(C), Presenter, received grant support from D.Z.I.C has received honoraria and was a consultant for Boehringer,  Ingelheim, Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL, Behring, Otsuka, Novartis, Youngene, Lexicon and NovoNordisk.  Boehringer IngelheimLilly, Merck, Janssen,Sanofi, AstraZeneca, CSL-Behring and Novo-Nordisk.

Faculty does plan to discuss the uses of an investigational product. Research studies/publications in the type 1 diabetes, and kidney disease spaces where there may/may not be indications in some places.